In the current global market environment, characterized by cautious Federal Reserve commentary and looming political uncertainties, investors are navigating a landscape of mixed economic signals. Despite these challenges, opportunities may exist in identifying stocks that are trading below their intrinsic value, offering potential for long-term growth as market conditions stabilize. In such a climate, a good stock is often one that demonstrates strong fundamentals and resilience amidst broader market volatility.

Top 10 Undervalued Stocks Based On Cash Flows

Click here to see the full list of 875 stocks from our Undervalued Stocks Based On Cash Flows screener.

Underneath we present a selection of stocks filtered out by our screen.

Overview: Revenio Group Oyj specializes in ophthalmological devices and software solutions for diagnosing glaucoma, macular degeneration, and diabetic retinopathy across Finland, Europe, North America, and internationally with a market cap of €714.37 million.

Operations: The company generates revenue of €102.49 million from its Health Tech segment, focusing on ophthalmological devices and software solutions.

Estimated Discount To Fair Value: 29.4%

Revenio Group Oyj is trading at €26.86, significantly below its estimated fair value of €38.02, indicating potential undervaluation based on cash flows. Despite a slight dip in third-quarter net income to €4.2 million from the previous year, revenues are projected to grow at 12.2% annually, outpacing the Finnish market’s growth rate of 2.6%. Additionally, earnings are expected to increase by 19% per year, surpassing local market expectations of 14.2%.

Overview: Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training across Europe, the Americas, Asia, and internationally, with a market cap of SEK8.24 billion.

Operations: The company generates revenue through its Industry/OEM segment, which accounts for SEK419.66 million, and its Educational Products segment, contributing SEK440.17 million.

Estimated Discount To Fair Value: 49.2%

Surgical Science Sweden is trading at SEK161.5, significantly below its estimated fair value of SEK317.61, suggesting undervaluation based on cash flows. Despite a decline in net income for Q3 and the first nine months of 2024 compared to the previous year, revenue is expected to grow by 17.7% annually, surpassing the Swedish market’s growth rate of 1.3%. Earnings are forecast to increase significantly at 36.1% per year, outpacing local expectations.

Overview: Mo-BRUK S.A. operates in the waste processing industry, handling industrial, hazardous, and municipal waste across several European countries including Poland, Germany, and Italy, with a market cap of PLN1.13 billion.

Operations: The company’s revenue segments include processing industrial waste (PLN 163.48 million), hazardous waste (PLN 173.92 million), and municipal waste (PLN 89.56 million).

Estimated Discount To Fair Value: 46.7%

Mo-BRUK is trading at PLN322, significantly below its estimated fair value of PLN603.73, indicating undervaluation based on cash flows. Despite a slight decline in net income for the first nine months of 2024 compared to the previous year, revenue and earnings are forecast to grow faster than the Polish market at 11.3% and 23.7% per annum respectively. However, its dividend yield of 4.09% is not well covered by free cash flows.

Turning Ideas Into Actions

• Click here to access our complete index of 875 Undervalued Stocks Based On Cash Flows.
• Shareholder in one or more of these companies? Ensure you’re never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Ready To Venture Into Other Investment Styles?

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.
It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]